Intralesional methotrexate for the treatment of keratoacanthoma: Retrospective study and review of the korean literature

Min Gun Yoo, Il-Hwan Kim

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Although intralesional methotrexate (MTX) is an effective, nonsurgical treatment of keratoacanthoma (KA), there have not been many reports of on the MTX treatment for KA in Korea. Objective: The purpose of this study was to evaluate the clinical efficacy of the intralesional MTX for the treatment of KA in Korean patients. Methods: We retrospectively studied seven patients with KA who received intralesional injection of MTX in our department. The efficacy was evaluated based on the physician assessment. Our review also included the cases of KA treated with intralesional MTX in Korean patients from the previous reports. We then analyzed the therapeutic regimens in the Korean patients by comparing them with the Caucasian patients. Results: We identified 11 cases of Korean KA patients treated with an intralesional MTX, including seven from our institution and four from the Korean literature. Ten of the 11 patients (91%) showed a complete resolution with an intralesional MTX. No adverse events were observed during the treatment and the follow-up periods. No recurrence was found during the follow-up. In therapeutic analysis, the Korean patients required 2 to 7 injections (mean 4.6 injections) to achieve a tumor resolution with the mean time to clearing at 7.6 weeks. Conclusion: Intralesional MTX can be an effective and safe non-operative treatment modality for most Koreans with KA. (Ann Dermatol 26(2) 172∼176, 2014).

Original languageEnglish
Pages (from-to)172-176
Number of pages5
JournalAnnals of Dermatology
Volume26
Issue number2
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Keratoacanthoma
Methotrexate
Retrospective Studies
Therapeutics
Intralesional Injections
Injections
Korea
Physicians
Recurrence

Keywords

  • Intralesional injection
  • Keratoacanthoma
  • Koreans
  • Methotrexate

ASJC Scopus subject areas

  • Dermatology

Cite this

Intralesional methotrexate for the treatment of keratoacanthoma : Retrospective study and review of the korean literature. / Yoo, Min Gun; Kim, Il-Hwan.

In: Annals of Dermatology, Vol. 26, No. 2, 01.01.2014, p. 172-176.

Research output: Contribution to journalArticle

@article{c7599519224a4b87ae43f5f6a7b3f413,
title = "Intralesional methotrexate for the treatment of keratoacanthoma: Retrospective study and review of the korean literature",
abstract = "Background: Although intralesional methotrexate (MTX) is an effective, nonsurgical treatment of keratoacanthoma (KA), there have not been many reports of on the MTX treatment for KA in Korea. Objective: The purpose of this study was to evaluate the clinical efficacy of the intralesional MTX for the treatment of KA in Korean patients. Methods: We retrospectively studied seven patients with KA who received intralesional injection of MTX in our department. The efficacy was evaluated based on the physician assessment. Our review also included the cases of KA treated with intralesional MTX in Korean patients from the previous reports. We then analyzed the therapeutic regimens in the Korean patients by comparing them with the Caucasian patients. Results: We identified 11 cases of Korean KA patients treated with an intralesional MTX, including seven from our institution and four from the Korean literature. Ten of the 11 patients (91{\%}) showed a complete resolution with an intralesional MTX. No adverse events were observed during the treatment and the follow-up periods. No recurrence was found during the follow-up. In therapeutic analysis, the Korean patients required 2 to 7 injections (mean 4.6 injections) to achieve a tumor resolution with the mean time to clearing at 7.6 weeks. Conclusion: Intralesional MTX can be an effective and safe non-operative treatment modality for most Koreans with KA. (Ann Dermatol 26(2) 172∼176, 2014).",
keywords = "Intralesional injection, Keratoacanthoma, Koreans, Methotrexate",
author = "Yoo, {Min Gun} and Il-Hwan Kim",
year = "2014",
month = "1",
day = "1",
doi = "10.5021/ad.2014.26.2.172",
language = "English",
volume = "26",
pages = "172--176",
journal = "Annals of Dermatology",
issn = "1013-9087",
publisher = "Korean Dermatological Association",
number = "2",

}

TY - JOUR

T1 - Intralesional methotrexate for the treatment of keratoacanthoma

T2 - Retrospective study and review of the korean literature

AU - Yoo, Min Gun

AU - Kim, Il-Hwan

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Although intralesional methotrexate (MTX) is an effective, nonsurgical treatment of keratoacanthoma (KA), there have not been many reports of on the MTX treatment for KA in Korea. Objective: The purpose of this study was to evaluate the clinical efficacy of the intralesional MTX for the treatment of KA in Korean patients. Methods: We retrospectively studied seven patients with KA who received intralesional injection of MTX in our department. The efficacy was evaluated based on the physician assessment. Our review also included the cases of KA treated with intralesional MTX in Korean patients from the previous reports. We then analyzed the therapeutic regimens in the Korean patients by comparing them with the Caucasian patients. Results: We identified 11 cases of Korean KA patients treated with an intralesional MTX, including seven from our institution and four from the Korean literature. Ten of the 11 patients (91%) showed a complete resolution with an intralesional MTX. No adverse events were observed during the treatment and the follow-up periods. No recurrence was found during the follow-up. In therapeutic analysis, the Korean patients required 2 to 7 injections (mean 4.6 injections) to achieve a tumor resolution with the mean time to clearing at 7.6 weeks. Conclusion: Intralesional MTX can be an effective and safe non-operative treatment modality for most Koreans with KA. (Ann Dermatol 26(2) 172∼176, 2014).

AB - Background: Although intralesional methotrexate (MTX) is an effective, nonsurgical treatment of keratoacanthoma (KA), there have not been many reports of on the MTX treatment for KA in Korea. Objective: The purpose of this study was to evaluate the clinical efficacy of the intralesional MTX for the treatment of KA in Korean patients. Methods: We retrospectively studied seven patients with KA who received intralesional injection of MTX in our department. The efficacy was evaluated based on the physician assessment. Our review also included the cases of KA treated with intralesional MTX in Korean patients from the previous reports. We then analyzed the therapeutic regimens in the Korean patients by comparing them with the Caucasian patients. Results: We identified 11 cases of Korean KA patients treated with an intralesional MTX, including seven from our institution and four from the Korean literature. Ten of the 11 patients (91%) showed a complete resolution with an intralesional MTX. No adverse events were observed during the treatment and the follow-up periods. No recurrence was found during the follow-up. In therapeutic analysis, the Korean patients required 2 to 7 injections (mean 4.6 injections) to achieve a tumor resolution with the mean time to clearing at 7.6 weeks. Conclusion: Intralesional MTX can be an effective and safe non-operative treatment modality for most Koreans with KA. (Ann Dermatol 26(2) 172∼176, 2014).

KW - Intralesional injection

KW - Keratoacanthoma

KW - Koreans

KW - Methotrexate

UR - http://www.scopus.com/inward/record.url?scp=84901817023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901817023&partnerID=8YFLogxK

U2 - 10.5021/ad.2014.26.2.172

DO - 10.5021/ad.2014.26.2.172

M3 - Article

AN - SCOPUS:84901817023

VL - 26

SP - 172

EP - 176

JO - Annals of Dermatology

JF - Annals of Dermatology

SN - 1013-9087

IS - 2

ER -